Exhibit 99.1

Recipharm Israel Ltd.

Audited Financial Statements as of December 31, 2025

Contents

- - - - - - - - - - - - - - -Report of Certified Public Accounting Firm

To the board of directors and shareholder of Recipharm Israel Ltd.

Opinion on Financial Statements

We have audited the accompanying financial statements of Recipharm Israel Ltd. (the “Company”), which comprise the statements of financial position as of December 31, 2025, and 2024, and the related statements of comprehensive loss, changes in deficit in equity, and cash flows for each of the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and 2024, and the results of its operations, changes in deficit in equity, and cash flows for each of the years then ended, in accordance with IFRS Accounting Standards. 

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements relevant to our audits of the financial statements, and we have fulfilled our other ethical responsibilities in accordance with those requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Substantial Doubt About the Company’s Ability to Continue as a Going Concern

Note 1A to the financial statements indicates that the Company incurred a loss of NIS 9,395 thousand for the year ended December 31, 2025, had a working capital deficit of NIS 22,819 thousand, and a deficit in equity of NIS 51,382 thousand as of that date. These conditions, together with the Company’s dependence on continued financial support from its Parent Company RECIPHARM OT AB, raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period.

As described in Note 1A, management’s plans regarding these matters are based primarily on continued financial support from the Parent Company. The financial statements have been prepared on a going concern basis and do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with IFRS Accounting Standards, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern, and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company’s financial reporting process.

Auditor’s Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS, we exercise professional judgment and maintain professional skepticism throughout the audit. We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and perform procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. We also obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control. Accordingly, no such opinion is expressed. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, evaluating the overall presentation of the financial statements, and concluding whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

Statements of Financial Position

The accompanying notes constitute an integral part of the financial statements

Statements of Comprehensive Loss

The accompanying notes constitute an integral part of the financial statements

Statements of Changes in Deficit in Equity

The accompanying notes constitute an integral part of the financial statements

Statements of Cash Flows

In these financial statements

The significant accounting policies described below have been applied consistently in the financial statements for all periods presented, except where otherwise indicated.

The financial statements have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB).

The Company’s functional currency and the presentation currency of the financial statements are NIS.

The functional currency is the currency that most accurately reflects the economic environment in which the Company operates and conducts its transactions, and in which its financial position and results of operations are measured.

Transactions denominated in a foreign currency (a currency different from the functional currency) are recorded at the exchange rate prevailing on the transaction date upon initial recognition. After initial recognition, financial assets and liabilities denominated in foreign currency are translated at each reporting date into the functional currency using the exchange rate at that date. Exchange differences are recognized in the statement of profit or loss. Non-financial assets and liabilities denominated in foreign currency, presented at cost, are translated using the exchange rate at the transaction date. Non-monetary assets and liabilities denominated in foreign currency and presented at fair value are translated into the functional currency at the exchange rate prevailing on the date the fair value was determined.

Cash and cash equivalents are defined by the Company as cash and highly liquid short-term deposits with banking corporations that are not restricted or pledged, with original maturity of up to three months from the date of investment.

The provision for doubtful debts is specifically determined with respect to debts that, based on the Company’s management’s estimate, are considered doubtful of collection. Customer balances for which an impairment loss has occurred are written off when it is determined that such balances are uncollectible.

Revenue is recognized in accordance with IFRS 15 when control of the promised services is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled. For service arrangements, revenue is recognized over time when the customer simultaneously receives and consumes the service benefits. Progress is measured based on actual hours incurred relative to total estimated hours when that input method faithfully depicts performance.

Revenue from rendering services

When the outcome of a service arrangement cannot be measured reliably, revenue is recognized only to the extent of recoverable costs incurred. The Company discloses significant judgments, performance obligations, contract assets and contract liabilities when material.

Property and equipment are presented at cost plus directly attributable acquisition costs, less accumulated depreciation and impairment losses, and excluding ongoing maintenance expenses. Cost includes spare parts and auxiliary equipment that are usable solely in relation to machinery and equipment.

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:

Leasehold improvements are depreciated on a straight-line basis over the lease term (including any extension option period that the Company is reasonably certain to exercise) or over the assets’ useful life, whichever is shorter. For impairment of property and equipment, see Section G below.

The Company evaluates the need for impairment of non-financial assets when indicators arising from events or changes in circumstances suggest that the carrying amount presented in the financial statements may not be recoverable.

When the carrying amount of non-financial assets exceeds their recoverable amount, the assets are written down to their recoverable amount. The recoverable amount is the higher of fair value less costs of disposal and value in use. In estimating value in use, the estimated future cash flows are discounted at a pre-tax discount rate that reflects the risks specific to the asset. For an asset that does not generate independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss.

Employee benefit expenses may include costs related to share-based incentive plans of the Recipharm group (the “plans”). Since 2014, Recipharm has annually invited employees to participate in various share-based incentive plans under which employees use their own funds to purchase shares at market price. Each of the aforementioned share-based incentive plans has a three-year term, and participants are granted one savings share for every share they purchase. Senior executives also receive performance shares based on actual performance relative to forecasts.

Transactions settled in equity instruments

The grant-date fair value of equity-settled awards is allocated over the vesting period and recognized as an employee benefits expense against equity. The fair value of the share is the market price at the grant date, adjusted for the value net of future dividends on shares not payable to employees. In each reporting period, the Company assesses its estimate of the number of shares expected to vest in accordance with vesting conditions unrelated to market performance. In the event of a change in original estimates, the Company recognizes the change in profit or loss and makes the necessary adjustment to equity. Additionally, the Company records provisions for expected payments to National Insurance. Such provisions are charged to profit or loss over the vesting period. Provisions are reviewed on an ongoing basis to confirm their alignment with the fair value of the shares as of the reporting date.

No share-based payment expense was recognized in profit or loss.

Post-employment benefits

The plans are generally funded by contributions to insurance companies and are classified as both defined contribution and defined benefit plans.

The Company has defined contribution plans in accordance with Section 14 of the Severance Pay Law, under which the Company makes regular contributions without having a legal or constructive obligation to make additional payments even if the fund accumulations are insufficient to cover all benefits payable to the employee in respect of service rendered during the current and prior periods.

Contributions to a defined contribution plan for severance or for benefits are recognized as an expense at the time of contribution to the plan, concurrently with the receipt of the employee’s labor services.

In preparing the financial statements in accordance with IFRS Accounting Standards, management is required to use estimates, assumptions and judgments that affect the application of accounting policies and the reported amounts of assets, liabilities, revenues, and expenses. Actual results may differ from these estimates. The estimates and assumptions underlying them are subject to continuous review. Changes in accounting estimates are recognized in the period in which they occur.

For transactions in which the Company acts as lessee, it recognizes, at the lease commencement date, a right-of-use asset together with a lease liability, except for leases with a lease term of 12 months or less and leases where the underlying asset is of low value, for which the Company has elected to recognize the lease payments as an expense in profit or loss on a straight-line basis over the lease term. In measuring the lease liability, the Company elected to apply the practical expedient permitted by the standard and did not separate lease components from non-lease components, such as management services, maintenance services and other services included in the same transaction.

In transactions where an employee is entitled to a vehicle from the Company as part of the terms of employment, the Company treats these transactions as employee benefits in accordance with IAS 19, and not as sublease transactions.

At the commencement date, the lease liability includes all lease payments not yet paid, discounted at the interest rate implicit in the lease if readily determinable, or otherwise at the Company’s incremental borrowing rate. After the commencement date, the Company measures the lease liability using the effective interest rate method.

The right-of-use asset at the commencement date is recognized at the amount of the lease liability, plus lease payments made at or before the commencement date and including any transaction costs incurred. The right-of-use asset is measured using the cost model and depreciated over its useful life or the lease term, whichever is shorter.

The following table presents the depreciation period for the relevant right-of-use asset category.

When indicators of impairment exist, the Company assesses the impairment of the right-of-use asset in accordance with IAS 36.

At the commencement date, the Company applies the index rate prevailing at that date to calculate future lease payments.

In transactions where the Company is the lessee, changes in the amount of future lease payments arising from a change in the index are remeasured (using the same discount rate applied to the lease liability) and adjusted against the balance of the right-of-use asset and recognized as a corresponding adjustment to the lease liability balance, only when such changes in cash flows result from a change in the index that is, at the date when the indexation of lease payments takes effect.

The non-cancellable lease term also includes periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, as well as periods covered by an option to terminate the lease when it is reasonably certain that the termination option will not be exercised.

In the event of a change in the estimate regarding the exercise of an extension option or the non-exercise of a termination option, the Company remeasures the lease liability balance in accordance with the updated lease term, using the discount rate at the date of the change in estimate, with the total adjustment recognized against the right-of-use asset balance until fully written off, and thereafter recognized in profit or loss.

When a modification to the lease terms does not reduce the scope of the lease and is not accounted for as a separate lease transaction, the Company remeasures the lease liability balance in accordance with the amended lease terms, applying the updated discount rate at the date of the modification, and recognizes the total change in the lease liability balance in the right-of-use asset balance.

When an amendment to the lease terms results in a reduction in the lease scope, the Company recognizes a gain or loss arising from the partial or full derecognition of the right-of-use asset and the lease liability. Subsequently, the Company remeasures the lease liability in accordance with the amended lease terms, based on the updated discount rate as of the modification date, and adjusts the total change in the lease liability against the right-of-use asset.

The Company has lease agreements, including leases for land and buildings used in its regular operations. On August 11, 2020, the Company entered into a lease agreement with P.L.A.R Asset Management Ltd. and R. Matri Law Firm for a period of 12 years.

Total interest expense on lease liabilities for 2025 and 2024 was NIS 401 thousand and NIS 418 thousand, respectively.

Disclosures regarding right-of-use assets

CURRENT LIABILITIES

Non-current liabilities

The corporate tax rate in Israel for 2025 and 2024 is 23%.

The Company has tax assessments considered final through and including the 2020 tax year.

Deferred tax assets have not been recognized in respect of business losses carried forward because it is not probable that sufficient taxable profits will be available against which those losses can be utilized in the foreseeable future.

On February 16, 2026, Scinai Immunotherapeutics Ltd. (“Scinai”) entered into a Share Purchase Agreement with Recipharm AB (the “Parent”), pursuant to which Scinai acquired all of the issued and outstanding shares of the Company for nominal consideration of EUR 1.

In addition, Scinai acquired from the Parent all rights, title and interest in a shareholder loan granted by the Parent to the Company, with an outstanding principal amount of approximately EUR 12.3 million and accrued interest of approximately EUR 1.6 million, for nominal consideration of EUR 1.

In connection with the transaction, and prior to its closing, the Parent committed to make a capital injection into the Company in an amount sufficient to ensure that, as of the closing date, the Company held cash of approximately EUR 2 million, in addition to funding certain pre-closing expenses.

- - - - - - - - - - - - - - - - - - - - - - - - - -

Exhibit 99.2

SCINAI IMMUNOTHERAPEUTICS LTD.

Pro Forma Consolidated Statement of Financial Position

As of

December 31, 2025

Management’s Introduction

The accompanying unaudited pro forma condensed consolidated financial information has been prepared by the management of Scinai Immunotherapeutics Ltd. (the “Company”). The unaudited pro forma condensed consolidated financial information gives effect to the acquisition of Scinai Biopharma Service Ltd. (formerly Recipharm Israel Ltd). by the Company, as if such transaction had occurred on the dates indicated.

The unaudited pro forma condensed consolidated financial information has been prepared in accordance with Article 11 of Regulation S-X and accounting principles generally accepted in the United States of America (“U.S. GAAP”), and, in the opinion of management, includes all adjustments necessary for a fair presentation.

The unaudited pro forma condensed consolidated financial information includes certain amounts that are based on management’s estimates and assumptions, and the accompanying notes provide a detailed description of the assumptions and adjustments performed in the preparation of such information. Pro forma condensed consolidated financial information is inherently based on assumptions and adjustments which are subjective in nature. Accordingly, actual results may differ from those reflected in the unaudited pro forma condensed consolidated financial information.

The unaudited pro forma condensed consolidated financial information has been prepared for illustrative purposes only and is not intended to represent the financial position or results of operations of the Company that would have actually occurred had the transaction been completed on the dates indicated. In addition, such information is not necessarily indicative of the future results of operations or financial position of the Company.

SCINAI IMMUNOTHERAPEUTICS LTD.

PRO FORMA CONDENSED CONSOLIDATED AND COMBINED STATEMENT OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data)

SCINAI IMMUNOTHERAPEUTICS LTD.

PRO FORMA CONDENSED CONSOLIDATED AND COMBINED STATEMENT OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data)

SCINAI IMMUNOTHERAPEUTICS LTD. 

PRO FORMA CONDENSED CONSOLIDATED AND COMBINED STATEMENT OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data)

The accompanying notes are an integral part of the condensed consolidated financial statements.

SCINAI IMMUNOTHERAPEUTICS LTD. 

NOTES TO PRO FORMA CONDENSED CONSOLIDATED AND COMBINED STATEMENT OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data and unless otherwise indicated)

The unaudited pro forma condensed consolidated statement of financial position as at December 31, 2025, and the unaudited pro forma condensed consolidated statements of operations for the two years then ended, have been prepared by management to give effect to the acquisition (the “Transaction”) by Scinai Immunotherapeutics Ltd. (the “Company” or “Scinai”) of 100% of the issued and outstanding share capital of Scinai Biopharma Service Ltd (formerly Recipharm Israel Ltd). (“Scinai Biopharma”).

On February 16, 2026, Scinai entered into a Share Purchase Agreement (the “SPA”) with Recipharm AB (the “Parent”), pursuant to which Scinai acquired all of the issued and outstanding shares of Scinai Biopharma for nominal consideration of EUR 1. In addition, Scinai acquired from the Parent all rights, title and interest in a shareholder loan granted by the Parent to Scinai Biopharma , with an outstanding principal amount of approximately EUR 12.3 million and accrued interest of approximately EUR 1.6 million, for nominal consideration of EUR 1.

In connection with the Transaction, and prior to closing, the Parent committed to make a capital injection into Scinai Biopharma in an amount sufficient to ensure that, as of the closing date, Scinai Biopharma held cash of approximately EUR 2 million, in addition to funding certain pre-closing expenses.

The unaudited pro forma financial information has been prepared as if the Transaction had occurred on January 1, 2024 for purposes of the statement of operations, and on December 31, 2025 for purposes of the statement of financial position.

The historical financial statements of Recipharm Israel Ltd. (now known as Scinai Biopharma Service Ltd.) were prepared in New Israeli Shekels (“NIS”). For the purposes of the unaudited pro forma financial information, the statement of financial position of Recipharm Israel Ltd. has been translated into U.S. dollars using the exchange rate in effect as at December 31, 2025, and the statement of operations has been translated using the average exchange rates for the year ended December 31, 2025. All amounts presented in the unaudited pro forma financial information are denominated in U.S. dollars.

The pro forma adjustments include (i) the elimination of Scinai Biopharma historical shareholders’ equity, (ii) the elimination of intercompany balances, including the shareholder loan acquired as part of the Transaction, (iii) the recognition of the capital injection made by the Parent prior to closing as an increase in equity, and (iv) to recognize a gain arising from the Transaction, based on a preliminary estimate of the difference between the assets and liabilities as presented in the pro forma financial information and the nominal consideration transferred. This amount is provisional and may change materially upon completion of the purchase price allocation (PPA) and may result in material adjustments to the carrying amounts of property, plant and equipment, lease-related assets and liabilities, identifiable intangible assets, deferred tax balances and any resulting gain from a bargain purchase or goodwill, if any, upon completion of management’s valuation analyses and the final determination of fair values as of the acquisition date.

The unaudited pro forma financial information is presented for illustrative purposes only and does not purport to represent what the Company’s financial position or results of operations would have been had the Transaction occurred on the dates assumed, nor is it indicative of future results.

The unaudited pro forma condensed consolidated financial information of Scinai Immunotherapeutics Ltd. (the “Company” or “Scinai”) has been derived from and includes:

(a) Scinai’s audited consolidated financial statements as at December 31, 2025, for which the U.S. dollar is the functional and reporting currency;

(b) Recipharm Israel Ltd.’s (now known as Scinai Biopharma Service Ltd.) audited financial statements as at December 31, 2025, for which the New Israeli Shekel (NIS) is the functional currency, and which have been translated into U.S. dollars for the purposes of the unaudited pro forma condensed consolidated financial information; and.

(c) the pro forma adjustments.

SCINAI IMMUNOTHERAPEUTICS LTD.

NOTES TO PRO FORMA CONDENSED CONSOLIDATED AND COMBINED STATEMENT OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data and unless otherwise indicated)

The unaudited pro forma condensed consolidated financial information should be read in conjunction with the above-described financial statements and the related notes thereto.

The unaudited pro forma condensed consolidated financial information is not necessarily indicative of the Company’s financial position or results of operations that would have been obtained had the Transaction been completed on the dates assumed, nor is it indicative of future results. In preparing this unaudited pro forma condensed consolidated financial information, no adjustments have been made to reflect additional costs or savings that may result from the Transaction.

The pro forma adjustments are based on preliminary estimates and assumptions, that is, they represent provisional amounts, as the initial accounting for the business combination has not yet been completed.

As of the date of this report, the purchase price allocation (“PPA”) has not yet been performed.

The actual allocation of the purchase price will be based on the fair value of the assets acquired and liabilities assumed as of the acquisition date and other information available at that time. Accordingly, the actual amounts recorded for each of the assets and liabilities may differ from the pro forma amounts presented herein, and such differences may be material.

Subsequent to the reporting period, on March 5, 2026, Recipharm Israel Ltd. changed its legal name to Scinai Biopharma Service Ltd., as evidenced by a Certificate of Change of Name issued by the Israeli Corporations Authority. This change had no impact on the Company’s financial position or results of operations and is presented for disclosure purposes only.

The accounting policies used in the preparation of this unaudited pro forma condensed consolidated and combined financial information are consistent with those of the Company, as described in its consolidated financial statements as of and for the year ended December 31, 2025, which were prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).

The financial statements of Recipharm Israel Ltd. as of December 31, 2025 were prepared in accordance with International Financial Reporting Standards (“IFRS”). For purposes of the unaudited pro forma condensed consolidated financial information, adjustments have been made to Recipharm Israel Ltd.’s financial statements to conform its accounting policies to those of the Company under U.S. GAAP.

The unaudited pro forma condensed consolidated financial information has been prepared based on the following adjustments and assumptions:

The translation of Recipharm Israel Ltd.’s (now known as Scinai Biopharma Service Ltd.) financial statements from New Israeli Shekels (“NIS”) into U.S. dollars. The statement of financial position was translated using the exchange rate in effect as of December 31, 2025, and the statement of operations was translated using the average exchange rates for the year then ended.

SCINAI IMMUNOTHERAPEUTICS LTD.

NOTES TO PRO FORMA CONDENSED CONSOLIDATED AND COMBINED STATEMENT OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data and unless otherwise indicated)

The above adjustments correspond to the amounts presented in the pro forma transaction adjustments column of the pro forma financial information.

The historical financial statements of Scinai Biopharma were prepared in accordance with IFRS, under which lease expenses are recognized as depreciation of right-of-use assets and interest on lease liabilities in accordance with IFRS 16.

For purposes of the unaudited pro forma condensed consolidated financial information, the Company has applied ASC 842, Leases, under which lease expense is recognized as a single cost on a straight-line basis over the lease term. Accordingly, depreciation of right-of-use assets and interest expense recognized under IFRS have been eliminated and replaced with a single lease expense.

SCINAI IMMUNOTHERAPEUTICS LTD.

NOTES TO PRO FORMA CONDENSED CONSOLIDATED AND COMBINED STATEMENT OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data and unless otherwise indicated)

In addition, the right-of-use asset and lease liabilities were remeasured based on the present value of the remaining lease payments over the revised lease term. As a result, the right-of-use asset was adjusted to approximately $1,287 thousand, reflecting a decrease of approximately $1,789 thousand.

Lease liabilities were adjusted to approximately $1,094 thousand, including a current portion of approximately $193 thousand. The adjustment resulted in a decrease of approximately $2,030 thousand in non-current lease liabilities and an increase of approximately $63 thousand in current lease liabilities.

As a result of these adjustments, operating expenses decreased and finance expenses were reduced due to the elimination of interest expense, resulting in a net decrease in total expenses of approximately $67 thousand and $61 thousand for the years ended December 31, 2025 and 2024, respectively.